Comprehensive analysis of circulating miRNA expression profiles in insulin resistance and type 2 diabetes in Qatari population

References

• Aghaei M, Khodadadian A, Elham K-N, Nazari M, Babakhanzadeh E. 2020. Major miRNA involved in insulin secretion and production in beta-cells. Int J Gen Med. 13:89.
   PubMed Web of Science ®Google Scholar
• Aljaibeji H, Elemam NM, Mohammed AK, Hasswan H, Thahyabat MA, Alkhayyal N, Sulaiman N, Taneera J. 2020. Let7b-5p is upregulated in the serum of Emirati patients with type 2 diabetes and regulates insulin secretion in INS-1 cells. Exp Clin Endocrinol Diabetes. doi:10.1055/a-1261-5282.
   PubMed Web of Science ®Google Scholar
• Allegra A, Alonci A, Campo S, Penna G, Petrungaro A, Gerace D, Musolino C. 2012. Circulating microRNAs: New biomarkers in diagnosis, prognosis and treatment of cancer (review). Int J Oncol. 41(6):1897–1912. doi:10.3892/ijo.2012.1647.
   PubMed Web of Science ®Google Scholar
• Alzaman N, Ali A. 2016. Obesity and diabetes mellitus in the Arab world. J Taibah Univ Med Sci. 11(4):301–309. doi:10.1016/j.jtumed.2016.03.009.
   Google Scholar
• Beale EG. 2013. Insulin signaling and insulin resistance. J Invest Med. 61(1):11. doi:10.2310/JIM.0b013e3182746f95.
   PubMed Web of Science ®Google Scholar
• Bermudez V, Salazar J, Martínez MS, Chávez-Castillo M, Olivar LC, Calvo MJ, Palmar J, Bautista J, Ramos E, Cabrera M, et al. 2016. Prevalence and associated factors of insulin resistance in adults from Maracaibo City, Venezuela. Adv Prev Med. 2016:9405105. doi: 10.1155/2016/9405105.
   PubMedGoogle Scholar
• Brown AE, Walker M. 2016. Genetics of insulin resistance and the metabolic syndrome. Curr Cardiol Rep. 18(8):75. doi:10.1007/s11886-016-0755-4.
   PubMed Web of Science ®Google Scholar
• Cai J, Wu J, Zhang H, Fang L, Huang Y, Yang Y, Zhu X, Li R, Li M. 2013. miR-186 downregulation correlates with poor survival in lung adenocarcinoma, where it interferes with cell-cycle regulation. Cancer Res. 73(2):756–766.
   PubMed Web of Science ®Google Scholar
• Chakraborty C, Doss CG, Bandyopadhyay S, Agoramoorthy G. 2014. Influence of miRNA in insulin signaling pathway and insulin resistance: micro-molecules with a major role in type-2 diabetes. Wiley Interdiscip Rev RNA. 5(5):697–712. doi:10.1002/wrna.1240.
   PubMed Web of Science ®Google Scholar
• Dard-Dascot C, Naquin D, d’Aubenton-Carafa Y, Alix K, Thermes C, van Dijk E. 2018. Systematic comparison of small RNA library preparation protocols for next-generation sequencing. BMC Genomics. 19(1):118. doi:10.1186/s12864-018-4491-6.
   PubMedGoogle Scholar
• DeFronzo RA, Tobin JD, Andres R. 1979. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 237(3):E214–E223. doi:10.1152/ajpendo.1979.237.3.E214.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Tripathy D. 2009. Skeletal muscle insulin resistance Is the Primary defect in type 2 diabetes. Diabetes Care. 32(suppl 2):S157. doi:10.2337/dc09-S302.
   PubMed Web of Science ®Google Scholar
• de Luca C, Olefsky JM. 2008. Inflammation and insulin resistance. FEBS Lett. 582(1):97–105. doi:10.1016/j.febslet.2007.11.057.
   PubMed Web of Science ®Google Scholar
• Deng J, Guo F. 2019. MicroRNAs and type 2 diabetes. ExRNA. 1(1):36. doi:10.1186/s41544-019-0038-5.
   Google Scholar
• Ding L, Zhang L, Biswas S, Schugar RC, Brown JM, Byzova T, Podrez E. 2017. Akt3 inhibits adipogenesis and protects from diet-induced obesity via WNK1/SGK1 signaling. JCI Insight. 2:22. doi:10.1172/jci.insight.95687.
   Web of Science ®Google Scholar
• Do HD, Lohsoonthorn V, Jiamjarasrangsi W, Lertmaharit S, Williams MA. 2010. Prevalence of insulin resistance and its relationship with cardiovascular disease risk factors among Thai adults over 35 years old. Diabetes Res Clin Pract. 89(3):303–308.
   PubMed Web of Science ®Google Scholar
• Dongiovanni P, Meroni M, Longo M, Fargion S, Fracanzani AL. 2018. miRNA signature in NAFLD: A turning point for a Non-invasive diagnosis. Int J Mol Sci. 19:12. doi:10.3390/ijms19123966.
   Web of Science ®Google Scholar
• Elemeery MN, Mohamed MA, Madkour MA, Shamseya MM, Issa NM, Badr AN, Ghareeb DA, Pan CH. 2019. MicroRNA signature in patients with hepatocellular carcinoma associated with type 2 diabetes. World J Gastroenterol. 25(42):6322–6341. doi:10.3748/wjg.v25.i42.6322.
   PubMed Web of Science ®Google Scholar
• Fahed M, Abou Jaoudeh MG, Merhi S, Mosleh JMB, Ghadieh R, Al Hayek S, Fares JEEH. 2020. Evaluation of risk factors for insulin resistance: a cross sectional study among employees at a private university in Lebanon. BMC Endocr Disord. 20(1):1–14.
   PubMed Web of Science ®Google Scholar
• Felekkis K, Touvana E, Stefanou C, Deltas C. 2010. microRNAs: a newly described class of encoded molecules that play a role in health and disease. Hippokratia. 14(4):236–240.
   PubMed Web of Science ®Google Scholar
• Flamment M, Hajduch E, Ferré P, Foufelle F. 2012. New insights into ER stress-induced insulin resistance. Trends Endocrinol Metab. 23(8):381–390. doi:10.1016/j.tem.2012.06.003.
   PubMed Web of Science ®Google Scholar
• Freeman AM, Pennings N. 2021. Insulin resistance. In: StatPearls [internet]. Treasure Island (FL): StatPearls Publishing.
   Google Scholar
• Friedrich N, Thuesen B, Jørgensen T, Juul A, Spielhagen C, Wallaschofksi H, Linneberg A. 2012. The association between IGF-I and insulin resistance: a general population study in Danish adults. Diabetes Care. 35(4):768–773.
   PubMed Web of Science ®Google Scholar
• Frost RJA, Olson EN. 2011. Control of glucose homeostasis and insulin sensitivity by the Let-7 family of microRNAs. Proc Natl Acad Sci USA. 108(52):21075–21080.
   PubMed Web of Science ®Google Scholar
• Gagliardino JJ, Atanasov PK, Chan JCN, Mbanya JC, Shestakova MV, Leguet-Dinville P, Annemans L. 2017. Resource use associated with type 2 diabetes in Africa, the Middle East, South Asia, Eurasia and Turkey: results from the International Diabetes Management Practice Study (IDMPS). BMJ Open Diabetes Res Care. 5(1):e000297. doi:10.1136/bmjdrc-2016-000297.
   PubMed Web of Science ®Google Scholar
• Glinge C, Clauss S, Boddum K, Jabbari R, Jabbari J, Risgaard B, Tomsits P, Hildebrand B, Kääb S, Wakili R, et al. 2017. Stability of circulating blood-based microRNAs – Pre-analytic methodological considerations. PloS one. 12(2):e0167969. doi:10.1371/journal.pone.0167969.
   PubMed Web of Science ®Google Scholar
• Hess AL, Larsen LH, Udesen PB, Sanz Y, Larsen TM, Dalgaard LT. 2020. Levels of circulating miR-122 are associated with weight loss and metabolic syndrome. Obesity. 28(3):493–501.
   PubMed Web of Science ®Google Scholar
• Hu J, Xu Y, Hao J, Wang S, Li C, Meng S. 2012. MiR-122 in hepatic function and liver diseases. Protein Cell. 3(5):364–371.
   PubMed Web of Science ®Google Scholar
• Huang RS, Gamazon ER, Ziliak D, Wen Y, Im HK, Zhang W, Wing C, Duan S, Bleibel WK, Cox NJ, Dolan ME. 2011. Population differences in microRNA expression and biological implications. RNA Biol. 8(4):692–701. doi:10.4161/rna.8.4.16029.
   PubMed Web of Science ®Google Scholar
• Hwang HW, Mendell JT. 2006. MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer. 94(6):776–780. doi:10.1038/sj.bjc.6603023.
   PubMed Web of Science ®Google Scholar
• Jaber LA, Brown MB, Hammad A, Zhu Q, Herman WH. 2004. The prevalence of the metabolic syndrome among Arab Americans. Diabetes Care. 27(1):234–238.
   PubMed Web of Science ®Google Scholar
• Jiang J, Mo H, Liu C, Wu B, Wu Z, Li X, Li T, He S, Li S, You Q, et al. 2018. Inhibition of miR–186–5p contributes to high glucose–induced injury in AC16 cardiomyocytes. Exp Ther Med. 15(1):627–632. doi:10.3892/etm.2017.5445.
   PubMed Web of Science ®Google Scholar
• Jiménez-Lucena R, Camargo A, Alcalá-Diaz JF, Romero-Baldonado C, Luque RM, van Ommen B, Delgado-Lista J, Ordovás JM, Pérez-Martínez P, Rangel-Zúñiga OA, López-Miranda J. 2018. A plasma circulating miRNAs profile predicts type 2 diabetes mellitus and prediabetes: from the CORDIOPREV study. Exp Mol Med. 50(12):1–12. doi:10.1038/s12276-018-0194-y.
   PubMed Web of Science ®Google Scholar
• Jones A, Danielson KM, Benton MC, Ziegler O, Shah R, Stubbs RS, Das S, Macartney-Coxson D. 2017a. miRNA signatures of insulin resistance in obesity. Obesity (Silver Spring). 25(10):1734–1744. doi:10.1002/oby.21950.
   PubMed Web of Science ®Google Scholar
• Juzenas S, Venkatesh G, Hübenthal M, Hoeppner MP, Du ZG, Paulsen M, Rosenstiel P, Senger P, Hofmann-Apitius M, Keller A, et al. 2017. A comprehensive, cell specific microRNA catalogue of human peripheral blood. Nucleic Acids Res. 45(16):9290–9301. doi:10.1093/nar/gkx706.
   PubMed Web of Science ®Google Scholar
• Kalan Farmanfarma KH, Ansari-Moghaddam A, Zareban I, Adineh HA. 2020. Prevalence of type 2 diabetes in middle–east: Systematic review& meta-analysis. Prim Care Diabetes. 14(4):297–304. doi:10.1016/j.pcd.2020.01.003.
   PubMed Web of Science ®Google Scholar
• Kim JK. 2009. Hyperinsulinemic-euglycemic clamp to assess insulin sensitivity in vivo. Methods Mol Biol. 560:221–238. doi:10.1007/978-1-59745-448-3_15.
   PubMedGoogle Scholar
• La Sala L, Micheloni S, De Nigris V, Prattichizzo F, Ceriello A. 2018. Novel insights into the regulation of miRNA transcriptional control: implications for T2D and related complications. Acta Diabetol. 55(10):989–998. doi:10.1007/s00592-018-1149-4.
   PubMed Web of Science ®Google Scholar
• Li Y, Kowdley KV. 2012. MicroRNAs in common human diseases. Genomics Proteomics Bioinformatics. 10(5):246–253. doi:10.1016/j.gpb.2012.07.005.
   PubMedGoogle Scholar
• Li Z, Wu J, Wei W, Cai X, Yan J, Song J, Wang C, Wang J. 2019. Association of serum miR-186-5p with the prognosis of acute coronary syndrome patients after percutaneous coronary intervention [original research]. Front Physiol. 10:686. doi:10.3389/fphys.2019.00686.
   PubMed Web of Science ®Google Scholar
• Ling C, Rönn T. 2016. Epigenetic markers to further understand insulin resistance. Diabetologia. 59(11):2295–2297. doi:10.1007/s00125-016-4109-y.
   PubMed Web of Science ®Google Scholar
• Ling H, Fabbri M, Calin GA. 2013. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov. 12(11):847–865. doi:10.1038/nrd4140.
   PubMed Web of Science ®Google Scholar
• Mall C, Rocke DM, Durbin-Johnson B, Weiss RH. 2013. Stability of miRNA in human urine supports its biomarker potential. Biomark Med. 7(4):623–631. doi:10.2217/bmm.13.44.
   PubMed Web of Science ®Google Scholar
• Martinez SC, Cras-Méneur C, Bernal-Mizrachi E, Permutt MA. 2006. Glucose regulates foxo1 through insulin receptor signaling in the pancreatic islet β-cell. Diabetes. 55(6):1581–1591. doi:10.2337/db05-0678.
   PubMed Web of Science ®Google Scholar
• Masotti A, Preckel T. 2006. Analysis of small RNAs with the Agilent 2100 bioanalyzer. Nat Methods. 3(8):658–658. doi:10.1038/nmeth908.
   Google Scholar
• Meo SA, Sheikh SA, Sattar K, Akram A, Hassan A, Meo AS, Usmani AM, Qalbani E, Ullah A. 2019. Prevalence of type 2 diabetes mellitus among men in the Middle East: a retrospective study. Am J Mens Health. 13(3):1557988319848577.
   Web of Science ®Google Scholar
• Mirmiran P, Sherafat Kazemzadeh R, Jalali Farahani S, Azizi F. 2010. Childhood obesity in the Middle East: a review. EMHJ-Eastern Mediterranean Health J. 16(9):1009–1017.
   PubMedGoogle Scholar
• Mori MA, Ludwig RG, Garcia-Martin R, Brandão BB, Kahn CR. 2019. Extracellular miRNAs: from biomarkers to mediators of physiology and disease. Cell Metab. 30(4):656–673. doi:10.1016/j.cmet.2019.07.011.
   PubMed Web of Science ®Google Scholar
• Muniyappa R, Lee S, Chen H, Quon MJ. 2008. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab. 294(1):E15–E26. doi:10.1152/ajpendo.00645.2007.
   PubMed Web of Science ®Google Scholar
• Myatt SS, Wang J, Monteiro LJ, Christian M, Ho K-K, Fusi L, Dina RE, Brosens JJ, Ghaem-Maghami S, Lam EWF. 2010. Definition of microRNAs that repress expression of the tumor suppressor gene FOXO1 in endometrial cancer. Cancer Res. 70(1):367–377.
   PubMed Web of Science ®Google Scholar
• Naja F, Nasreddine L, Hwalla N, Moghames P, Shoaib H, Fatfat M, Sibai A, Gali-Muhtasib H. 2012. Association of H. pylori infection with insulin resistance and metabolic syndrome among Lebanese adults. Helicobacter. 17(6):444–451.
   PubMed Web of Science ®Google Scholar
• Nigi L, Grieco GE, Ventriglia G, Brusco N, Mancarella F, Formichi C, Dotta F, Sebastiani G. 2018. MicroRNAs as regulators of insulin signaling: Research updates and potential therapeutic perspectives in type 2 diabetes. Int J Mol Sci. 19:12. doi:10.3390/ijms19123705.
   Web of Science ®Google Scholar
• Ortega FJ, Mercader JM, Catalán V, Moreno-Navarrete JM, Pueyo N, Sabater M, Gómez-Ambrosi J, Anglada R, Fernández-Formoso JA, Ricart W, et al. 2013. Targeting the circulating microRNA signature of obesity. Clin Chem. 59(5):781–792. doi:10.1373/clinchem.2012.195776.
   PubMed Web of Science ®Google Scholar
• Ortega FJ, Mercader JM, Moreno-Navarrete JM, Rovira O, Guerra E, Esteve E, Xifra G, Martínez C, Ricart W, Rieusset J. 2014. Profiling of circulating microRNAs reveals common microRNAs linked to type 2 diabetes that change with insulin sensitization. Diabetes Care. 37(5):1375–1383.
   PubMed Web of Science ®Google Scholar
• O-Sullivan I, Zhang W, Wasserman DH, Liew CW, Liu J, Paik J, DePinho RA, Stolz DB, Kahn CR, Schwartz MW, Unterman TG. 2015. Foxo1 integrates direct and indirect effects of insulin on hepatic glucose production and glucose utilization. Nat Commun. 6(1):7079. doi:10.1038/ncomms8079.
   PubMedGoogle Scholar
• Othman N, Nagoor NH. 2014. The role of microRNAs in the regulation of apoptosis in lung Cancer and Its application in Cancer treatment. BioMed Res Int. 2014:318030. doi:10.1155/2014/318030.
   PubMed Web of Science ®Google Scholar
• Qu H-Q, Li Q, Rentfro AR, Fisher-Hoch SP, McCormick JB. 2011. The definition of insulin resistance using HOMA-IR for Americans of Mexican descent using machine learning. PloS one. 6(6):e21041.
   PubMed Web of Science ®Google Scholar
• Roser AE, Caldi Gomes L, Schünemann J, Maass F, Lingor P. 2018. Circulating miRNAs as diagnostic biomarkers for Parkinson’s disease [mini review]. Front Neurosci. 12:625. doi:10.3389/fnins.2018.00625.
   PubMed Web of Science ®Google Scholar
• Rottiers V, Näär AM. 2012. MicroRNAs in metabolism and metabolic disorders. Nat Rev Mol Cell Biol. 13(4):239–250. doi:10.1038/nrm3313.
   PubMed Web of Science ®Google Scholar
• Schickel R, Boyerinas B, Park SM, Peter ME. 2008. MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene. 27(45):5959–5974. doi:10.1038/onc.2008.274.
   PubMed Web of Science ®Google Scholar
• Shaath H, Toor SM, Nair VS, Elkord E, Alajez NM. 2019. Transcriptomic analyses revealed systemic alterations in gene expression in circulation and tumor microenvironment of colorectal cancer patients. CancerS (Basel. 11:12. doi:10.3390/cancers11121994.
   Web of Science ®Google Scholar
• Shanik MH, Xu Y, Skrha J, Dankner R, Zick Y, Roth J. 2008. Insulin resistance and hyperinsulinemia: is hyperinsulinemia the cart or the horse? Diabetes Care. 31(Suppl 2):S262–S268. doi:10.2337/dc08-s264.
   PubMed Web of Science ®Google Scholar
• Taheri M, Eghtedarian R, Ghafouri-Fard S, Omrani MD. 2020. Non-coding RNAs and type 2 diabetes mellitus. Arch Physiol Biochem. 1–10. doi:10.1080/13813455.2020.1843498.
   Google Scholar
• Tam CS, Xie W, Johnson WD, Cefalu WT, Redman LM, Ravussin E. 2012. Defining insulin resistance from hyperinsulinemic-euglycemic clamps. Diabetes Care. 35(7):1605–1610. doi:10.2337/dc11-2339.
   PubMed Web of Science ®Google Scholar
• Taylor R. 2012. Insulin resistance and type 2 diabetes. Diabetes. 61(4):778. doi:10.2337/db12-0073.
   PubMed Web of Science ®Google Scholar
• Tuck MK, Chan DW, Chia D, Godwin AK, Grizzle WE, Krueger KE, Rom W, Sanda M, Sorbara L, Stass S, et al. 2009. Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group. J Proteome Res. 8(1):113–117. doi:10.1021/pr800545q.
   PubMed Web of Science ®Google Scholar
• Tüfekci KU, Meuwissen RL, Genç S. 2014. The role of microRNAs in biological processes. Methods Mol Biol. 1107:15–31. doi:10.1007/978-1-62703-748-8_2.
   PubMedGoogle Scholar
• Uwaifo GI, Parikh SJ, Keil M, Elberg J, Chin J, Yanovski JA. 2002. Comparison of insulin sensitivity, clearance, and secretion estimates using euglycemic and hyperglycemic clamps in children. J Clin Endocrinol Metab. 87(6):2899–2905. doi:10.1210/jcem.87.6.8578.
   PubMed Web of Science ®Google Scholar
• Wahid F, Shehzad A, Khan T, Kim YY. 2010. MicroRNAs: synthesis, mechanism, function, and recent clinical trials. Biochim Biophys Acta Mol Cell Res. 1803(11):1231–1243. doi:10.1016/j.bbamcr.2010.06.013.
   PubMed Web of Science ®Google Scholar
• Wang H, Peng R, Wang J, Qin Z, Xue L. 2018a. Circulating microRNAs as potential cancer biomarkers: the advantage and disadvantage. Clin Epigenetics. 10:59. doi:10.1186/s13148-018-0492-1.
   PubMed Web of Science ®Google Scholar
• Wang R, Bao H, Zhang S, Li R, Chen L, Zhu Y. 2018b. miR-186-5p promotes apoptosis by Targeting IGF-1 in SH-SY5Y OGD/R model. Int J Biol Sci. 14(13):1791–1799. doi:10.7150/ijbs.25352.
   PubMed Web of Science ®Google Scholar
• Wang R, Hong J, Cao Y, Shi J, Gu W, Ning G, Zhang Y, Wang W. 2015. Elevated circulating microRNA-122 is associated with obesity and insulin resistance in young adults. Eur J Endocrinol. 172(3):291–300. doi:10.1530/eje-14-0867.
   PubMed Web of Science ®Google Scholar
• Wang RH, Kim HS, Xiao C, Xu X, Gavrilova O, Deng CX. 2011. Hepatic Sirt1 deficiency in mice impairs mTorc2/Akt signaling and results in hyperglycemia, oxidative damage, and insulin resistance. J Clin Invest. 121(11):4477–4490. doi:10.1172/jci46243.
   PubMed Web of Science ®Google Scholar
• Wang Z, Sha HH, Li HJ. 2019. Functions and mechanisms of miR-186 in human cancer. Biomed Pharmacother. 119:109428. doi:10.1016/j.biopha.2019.109428.
   PubMed Web of Science ®Google Scholar
• Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH, Lee MJ, Galas DJ, Wang K. 2010. The microRNA spectrum in 12 body fluids. Clin Chem. 56(11):1733–1741. doi:10.1373/clinchem.2010.147405.
   PubMed Web of Science ®Google Scholar
• Willeit P, Skroblin P, Moschen AR, Yin X, Kaudewitz D, Zampetaki A, Barwari T, Whitehead M, Ramírez CM, Goedeke L. 2017. Circulating microRNA-122 is associated with the risk of new-onset metabolic syndrome and type 2 diabetes. Diabetes. 66(2):347–357.
   PubMed Web of Science ®Google Scholar
• Wu H, Ballantyne CM. 2020. Metabolic Inflammation and insulin resistance in obesity. Circ Res. 126(11):1549–1564. doi:10.1161/CIRCRESAHA.119.315896.
   PubMed Web of Science ®Google Scholar
• Wu S, Han M, Zhang C. 2019. Overexpression of microRNA-186 inhibits angiogenesis in retinoblastoma via the hedgehog signaling pathway by targeting ATAD2. J Cell Physiol. 234(10):19059–19072.
   PubMed Web of Science ®Google Scholar
• Yamada H, Suzuki K, Ichino N, Ando Y, Sawada A, Osakabe K, Sugimoto K, Ohashi K, Teradaira R, Inoue T. 2013. Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver. Clin Chim Acta. 424:99–103.
   PubMed Web of Science ®Google Scholar
• Yan LN, Zhang X, Xu F, Fan YY, Ge B, Guo H, Li ZL. 2020. Four-microRNA signature for detection of type 2 diabetes. World J Clin Cases. 8(10):1923–1931. doi:10.12998/wjcc.v8.i10.1923.
   PubMed Web of Science ®Google Scholar
• Yaribeygi H, Katsiki N, Behnam B, Iranpanah H, Sahebkar A. 2018. MicroRNAs and type 2 diabetes mellitus: molecular mechanisms and the effect of antidiabetic drug treatment. Metabolism. 87:48–55. doi:10.1016/j.metabol.2018.07.001.
   PubMed Web of Science ®Google Scholar
• Ye J. 2013. Mechanisms of insulin resistance in obesity. Front Med. 7(1):14–24. doi:10.1007/s11684-013-0262-6.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Xu L, Liu X, Wang Y. 2018. Evaluation of insulin sensitivity by hyperinsulinemic-euglycemic clamps using stable isotope-labeled glucose. Cell Discov. 4(1):17. doi:10.1038/s41421-018-0016-3.
   PubMedGoogle Scholar